Novo Nordisk Aktie 461641 / US6701002056
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
|
18.09.2025 17:57:36
|
Novo Nordisk Announces Encouraging Data From REACH Real-World Study, Stock Up
(RTTNews) - Novo Nordisk A/S (NVO), Thursday announced findings from the REACH real-world study, evaluating the cardiovascular disease-related outcomes of the once-weekly GLP-1 RA class, compared to glucose-lowering therapies.
The study, involving nearly 60,000 US Medicare patients, demonstrated that compared to dulaglutide, Ozempic was associated with a reduced risk of major adverse cardiovascular events such as a heart attack or stroke by 23 percent.
Additionally, the findings showed that once-weekly semaglutide was also associated with a 25 percent risk reduction of heart attack, stroke, hospitalization for unstable angina or heart failure, and death from any cause.
Currently, NVO is trading at $61.49, up 5.66 percent on the New York Stock Exchange.